LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

随着靶向药物的迅猛发展，许多肺癌患者已经从EGFR、ALK、ROS1等靶向药中获益，实现了较长的生存期。然而，靶向药的“蜜月期”往往短暂——耐药问题迟早会找上门，患者和医生的共同敌人就是那无情的“耐药”。一旦靶向药失效，治疗手段就显得捉襟见肘，多数患 ...

Smith also points out that the focus on Dato-DXd has overshadowed AstraZeneca’s promising non-oncology pipeline, which is expected to deliver significant developments between 2025 and 2028.

Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...

For more information visit ClinicalTrials.gov. Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo's proprietary ...